معرفی
Luis A. Martinez, PhD, serves as Associate Professor in the Department of Pathology at Stony Brook University's Renaissance School of Medicine. His laboratory investigates how mutant p53 proteins drive cancer progression through gain-of-function mechanisms, with particular focus on transcriptional regulation and immune modulation pathways.
Education:
- University of Texas at Austin: B.A. in Biological Sciences (1994)
- University of Texas at Austin: Ph.D. in Biology (1998)
Dr. Martinez's research has established that mutant p53 forms oncogenic complexes with ETS2 transcription factor, stabilizing ETS2 by disrupting ubiquitin-mediated degradation to amplify gene regulation. His recent work reveals mutant p53's role in suppressing innate immune signaling and engaging the cGAS/STING pathway for tumor suppression, demonstrating an evolution from transcriptional mechanisms toward immune-cancer interactions.
Publication trends show increasing focus on immune-oncology interfaces since 2021, building upon earlier foundational work in transcriptional regulation (2012-2015). This progression highlights expanding research scope into therapeutic resistance mechanisms and tumor microenvironment interactions.
No scientific awards were documented in the source material.
Dr. Martinez mentors graduate students through Stony Brook's Basic Sciences Graduate Programs, with research conducted in his laboratory located in the Basic Science Tower (Level 9, Room 103). While specific grant details weren't provided, his work spans molecular mechanisms of p53 mutations, chemoresistance, and immune evasion pathways.
His laboratory maintains active research into mutant p53/ETS2 complex dynamics and therapeutic targeting opportunities, with future work focused on dissecting transcriptional regulation mechanisms and protein interactions in tumor progression.
